Developing synthetic DNA vaccines for cancers and infectious diseases

Inovio has developed a powerful technology platform to facilitate the discovery, development and delivery of a new generation of novel vaccines: synthetic DNA vaccines. These highly optimized synthetic vaccines are able to induce strong antibody and T-cell responses. With their novel design of consensus antigens, these vaccines may enable our immune systems to protect against changing strains of a pathogen such as influenza or fight against cancerous cells. Our R&D efforts are revolutionizing vaccines and may forever change the course of modern medicine.

Our strategy is to use this platform to create a broad pipeline of vaccines to treat cancers and challenging infectious diseases that are today untreatable or are poorly treated. Inovio is advancing its growing pipeline of SynCon® vaccines for cancers and infectious diseases both independently and through the support of funding sponsorships, collaborations, and partnerships. We have ongoing dialog with prospective collaborators and partnerships to provide further development funding and create a commercialization path for promising vaccine candidates.

Our broad pipeline includes vaccines against diseases such as HIV and malaria that may be vital to improving health in developing countries as well as diseases such as influenza and cancers of the prostate and cervix that still require better solutions in developed countries. We have a robust research and preclinical program that rigorously assesses new vaccine candidates and has resulted in multiple vaccines progressing into clinical studies, with our most advanced program now in phase II.